{"filings":[{"id":805636,"accession_number":"0001171843-26-003877","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-06-02T20:01:17+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 400,000-share increase in 2021 Incentive Plan and amendment to ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected John Duke and Katherine A. Eade as Class II directors for three-year terms.","Ratified Grant Thornton LLP as independent auditor for FY2026; 2,781,705 votes for, 13,975 against.","Non-binding advisory vote approved named executive officer compensation: 1,768,695 for, 57,111 against.","Amended ESPP increases authorized shares from 310,000 to 1,900,000 (approx. 1.59M share increase).","Amended 2021 Incentive Plan increases authorized shares by 400,000 (from 646,520 available as of Dec 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22485,"accession_number":"0001171843-26-003271","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-05-12T11:30:20+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harvard Bioscience furnishes May 2026 investor presentation with no material new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide presentation attached as Exhibit 99.1; only cover page and forward-looking disclaimer provided in filing.","No specific financial figures, guidance updates, or operational targets were disclosed in the exhibit.","Presentation is furnished under Regulation FD and not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22486,"accession_number":"0001171843-26-003270","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-05-12T11:30:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q1 revenue $20.8M, gross margin 59%; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $20.8M (down 5% YoY from $21.8M); net loss $(3.4)M vs $(50.3)M including $48M impairment.","Gross margin 59% (vs 56% prior year); driven by higher-margin NPI mix (MeshMEA, BTX, SoHo).","Adjusted EBITDA $0.8M flat YoY; cash used in ops $(0.7)M vs $3.0M in Q1 2025.","Reaffirms full-year 2026 guidance; manufacturing consolidation on track for efficiencies."],"consensus_eps_estimate":-0.6324,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":20755000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101480,"accession_number":"0001171843-26-001614","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harvard Bioscience posts March 2026 investor presentation; no specific new data in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing attaches corporate slide deck dated March 2026; only cover page and forward-looking statement provided.","No financial results, guidance changes, or material events disclosed in the 8-K or exhibit excerpt.","Presentation is routinely updated for investor conferences; full content not visible in this filing.","Investors should review complete presentation for any operational or strategic updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101479,"accession_number":"0001171843-26-001504","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience 2025 revenue $86.6M, net loss $56.7M incl $48M goodwill impairment; permanent CFO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).","Full-year net loss $56.7M driven by $48.0M goodwill impairment in Q1 2025.","Adjusted EBITDA $8.1M for FY2025 vs $7.2M in FY2024; operating cash flow $6.7M vs $1.4M.","Interim CFO Mark Frost appointed permanent CFO effective March 12, 2026.","Introduced FY2026 guidance for revenue growth from new translational science products; no specific figures provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101478,"accession_number":"0001171843-26-001447","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harvard Bioscience amends CEO pay, appoints Frost as CFO with $375k base","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO John Duke gets base salary $515k; $100k cash bonus tied to credit facility refinancing.","CEO eligible for annual cash incentive up to 80% of base; target 75k RSUs post 1:10 reverse split.","CFO Mark Frost appointed effective March 6, 2026; salary $375k, annual cash incentive up to 60%.","Frost's target equity grant for 2026 is 30k RSUs post reverse split; agreements run through 2027.","Reverse stock split (1:10) takes effect March 13, 2026 as previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101477,"accession_number":"0001171843-26-001384","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience shareholders approve 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at March 6, 2026 special meeting; 27.0M votes for, 678K against.","Board set final ratio at 1-for-10; Charter amendment filed with Delaware Secretary of State.","Effective time 4:30 p.m. ET on March 13, 2026; split-adjusted trading begins March 16, 2026 under same symbol HBIO.","Outstanding shares reduced from ~44.7M to ~4.47M; authorized shares unchanged at 80M.","No fractional shares issued; stockholders entitled to cash payment in lieu based on closing price on March 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101476,"accession_number":"0001171843-26-000721","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience preliminary Q4 revenue $23.7M, adj EBITDA $3.8M, 27% YoY growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 revenue $23.7M, above guidance midpoint; gross margin 60% at high end of 58-60% range.","Adjusted EBITDA $3.8M, up 27% YoY, driven by cost reductions and expense management.","2026 outlook: year-over-year revenue growth and mid-to high-single-digit adjusted EBITDA growth.","Strategy focuses on translational science tools, consumables expansion (55% recurring revenue), and operational excellence.","Full Q4 and FY2025 results to be released March 12, 2026."],"consensus_eps_estimate":0.357,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":86550000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101475,"accession_number":"0001171843-26-000516","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Harvard Bioscience to close Holliston facility; expects $4M annual savings from 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closes Holliston, MA plant; moves US production to Minneapolis, MN; some operations to Germany, Sweden, UK.","Project Viking: ~$3M cost savings in 2027, ~$4M annual from 2028 from overhead reduction and SKU rationalization.","Pre-tax restructuring charges estimated $3.4-4.4M, including non-cash asset write-offs of $0.6-0.7M.","Consolidation substantially complete by first half 2027; Holliston stays operational through 2026 for continuity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101474,"accession_number":"0001171843-26-000343","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Harvard Bioscience reduces stockholder meeting quorum to one-third of shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment reducing quorum requirement for stockholder meetings from a majority to one-third of voting shares.","Amendment effective January 19, 2026, upon Board adoption; filed as Exhibit 3.1.","No other changes to bylaws disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101473,"accession_number":"0001171843-26-000203","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harvard Bioscience publishes investor update slide presentation","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide deck covers business strategy and outlook; no specific financial results or guidance changes.","Presentation is furnished under Item 7.01 and not filed for Exchange Act purposes.","Ticker: HBIO; no new material information disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117839,"accession_number":"0001171843-25-007972","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","1.02","2.03","5.02","9.01"],"status":"ready","headline":"Harvard Bioscience closes $40M debt refinancing with BroadOak; extends maturity to 2029, appoints new director","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Enters $40M senior secured credit facility (Term A $10M, Term B $22.5M, Term C $7.5M convertible at $1.00) maturing Dec 17, 2029","Issues warrants to purchase 2M shares of common stock at $0.50 per share; proceeds repay existing Citizens Bank credit facility","Quarterly amortization on Term A/B begins Dec 31, 2027; amortization and maturity can extend 1 year upon EBITDA milestone","Appoints Bill Snider (BroadOak Partner) to Board and Compensation Committee; will form Product, Operations & Scientific Advisory Board"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117838,"accession_number":"0001171843-25-007776","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Harvard Bioscience on track to refinance or repay credit agreement in Q4 2025","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Company in ongoing discussions to refinance or repay its existing credit agreement dated December 22, 2020.","Credit agreement involves Citizens Bank, Wells Fargo Bank, and First-Citizens Bank & Trust Company.","Refinancing or repayment expected to be completed during the fourth quarter of 2025.","No financial details or terms of the refinancing have been disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117837,"accession_number":"0001171843-25-007071","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HBIO Q3: revenues $20.6M, net loss narrows to $1.2M; Q4 guidance $22.5-$24.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenues $20.6M (down 6.4% YoY); gross margin 58.4% vs 58.1%.","Net loss ($1.2M) vs ($4.8M) YoY; adjusted EBITDA $2.0M vs $1.3M.","Cash from operations $1.1M positive vs ($0.8M) in Q3 2024.","Company in active discussions to refinance or repay credit agreement in Q4.","Q4 guidance: revenues $22.5M-$24.5M, gross margin 58%-60%; cites increased demand and backlog."],"consensus_eps_estimate":0.051,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":62815000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117836,"accession_number":"0001171843-25-006260","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Harvard Bioscience gets 180-day Nasdaq bid-price extension, transfers to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted until March 30, 2026 to reach $1.00 minimum bid price for 10 consecutive days.","Common stock transferred from Nasdaq Global Market to Capital Market effective October 3, 2025; ticker HBIO remains.","Company previously disclosed deficiency in April 2025 when bid price fell below $1.00 for 30 consecutive days.","If compliance not met by March 30, 2026, delisting proceedings may begin; Company may consider a reverse stock split.","No assurance of regaining compliance; Company will monitor closing bid price and evaluate options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134287,"accession_number":"0001171843-25-005787","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Harvard Bioscience appoints Stephen DeNelsky to board, effective Sept 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen DeNelsky, Managing Director at Oaktree Capital Management, appointed to Board and Nominating & Governance Committee.","He has 30 years of healthcare equity research/valuation experience across life sciences, pharma, devices.","Compensation includes 110,000 RSUs and $91,000 annual cash retainer (total ~$135,000) for non-employee director.","DeNelsky also serves on board of Visioncare Inc and previously on Integrated Diagnostics and AMICAS.","No arrangement for his selection as director and no family relationships with other directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134286,"accession_number":"0001171843-25-005377","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harvard Bioscience grants Interim CFO Mark Frost $100K retention bonus tied to debt refinancing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retention bonus of $100,000 for Interim CFO Mark Frost upon successful refinancing of term loan and revolver before March 15, 2026.","Replaces prior $50,000 cash bonus from the April 10, 2025 offer letter.","If terminated without cause before retention date, receives 5 months base salary and COBRA continuation.","Refinancing refers to company's existing term loan and senior revolving credit facility; Board determines success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134285,"accession_number":"0001171843-25-005288","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Harvard Bioscience gets covenant waiver, interest rate jumps to SOFR+700bps; going concern doubt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Waived defaults for failing Q2 2025 financial covenants; no covenant test for Q3 2025.","Interest rate increased to SOFR+700bps (ABR+650bps); $0.4M fee (1% of debt) payable.","Must take steps toward refinancing by Dec 5, 2025 or face default; mandatory prepayment on refinancing/sale.","Minimum liquidity of $3M required; company warns of substantial doubt about going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134284,"accession_number":"0001171843-25-005262","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.","Net loss improved to ($2.3M) from ($2.9M); adjusted EBITDA rose to $1.5M from $1.3M.","Cash from operations was $2.8M, compared to ($0.8M) in Q2 2024.","Credit agreement amended waiving defaults; new refinance deadline set for December 5, 2025.","Q3 2025 revenue guidance $19M-$21M with gross margin 56%-58%."],"consensus_eps_estimate":-0.102,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":42224000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134283,"accession_number":"0001171843-25-004508","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.","John Duke (current board member) appointed CEO effective July 28; base salary $480K, 500k RSU grant.","Rob Gagnon and Seth Benson appointed to Board; Gagnon to chair Audit and Compensation committees.","Preliminary Q2 2025 revenue of $20.4 million; gross margin guidance reiterated at 55%-57%.","Full Q2 2025 financial results expected to be reported on August 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151072,"accession_number":"0001171843-25-004196","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K/A","filed_at":"2025-06-27T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Harvard Bioscience misses audit committee independence; Nasdaq confirms; cure period through June 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Alan Edrick resigned from Board and Audit Committee effective June 10, 2025, leaving only two audit committee members.","Nasdaq Staff notified Company on June 26, 2025 that it no longer meets Audit Committee Composition Requirement (Rule 5605(c)(2)(A)).","Company has cure period until earlier of next annual meeting or June 10, 2026 to fill vacancy with independent director.","Company intends to appoint a new independent Board member expeditiously to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151078,"accession_number":"0001171843-25-004036","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Harvard Bioscience out of compliance with Nasdaq audit committee rule after board resignation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified Nasdaq on June 18, 2025 of non-compliance with Listing Rule 5605(c)(2)(A) due to Alan Edrick's resignation.","Audit Committee now has only two members; one vacancy from Edrick's departure effective June 10, 2025.","Cure period runs until earlier of next annual meeting or June 10, 2026; company plans to appoint independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151077,"accession_number":"0001171843-25-003882","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Alan Edrick resigns from Harvard Bioscience board effective June 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Edrick resigned from the board of directors, effective June 10, 2025.","Resignation is not due to any disagreement with the Company's operations, policies, or practices.","No successor has been named or announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151076,"accession_number":"0001171843-25-003574","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Harvard Bioscience appoints John Duke to board; incentive share pool increases 3.9M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Duke appointed to board effective June 2, 2025; will serve on audit and nominating committees.","Thomas Loewald resigned from board effective May 30, 2025; no disagreement cited.","Katherine Eade named Lead Independent Director.","Shareholders approved Amended and Restated 2021 Incentive Plan, increasing authorized shares by 3,923,000.","Non-binding advisory vote on executive compensation passed with 23.8M for vs 2.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151075,"accession_number":"0001171843-25-003044","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.","Gross margin 56.0% vs 60.3% YoY; Adjusted EBITDA $0.8M vs $1.6M YoY.","Q2 2025 guidance: revenue $18M-$20M, gross margin 55%-57%.","CEO cites NIH funding uncertainty, tariff impact on China sales; cost savings ~$1M/qtr starting Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":21774000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151074,"accession_number":"0001171843-25-002238","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harvard Bioscience director Bertrand Loy not standing for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bertrand Loy informed company April 10, 2025, he will not stand for re-election at the 2025 Annual Meeting.","Loy has served on the Board since 2014; currently Lead Independent Director and member of Audit and Nominating & Governance committees.","Decision not due to any disagreement with company's operations, policies, or practices; Loy continues as director until the meeting.","Board expressed appreciation for Loy's service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151073,"accession_number":"0001171843-25-002149","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["3.01","5.02","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience receives Nasdaq bid-price deficiency; CFO Cote resigns effective May 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified HBIO on April 4, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure through Oct 1, 2025.","CFO Jennifer Cote resigns effective upon filing Q1 10-Q (due by May 12, 2025); resignation not due to any disagreement.","Mark Frost appointed interim CFO and Treasurer effective on Cote's departure; base salary $320k, $50k bonus tied to full debt repayment.","Frost receives 100k time-based RSUs vesting in one year, with pro-rata vesting if terminated without cause.","If not cured, HBIO may transfer to Nasdaq Capital Market for second 180-day period or face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169972,"accession_number":"0001171843-25-001422","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.","Full-year 2024 revenue $94.1M vs $112.3M; net loss $(12.4)M vs $(3.4)M.","Adjusted EBITDA fell to $7.2M from $14.6M; operating cash flow dropped to $1.4M from $14.0M.","CEO cites challenging market; highlights SoHo telemetry and MeshMEA organoid systems as growth drivers.","Q4 net income was $18K vs loss of $(1.8)M in Q4 2023 (slight improvement in quarter)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169971,"accession_number":"0001171843-25-001416","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience enters debt waiver and amendment; substantial doubt about going concern","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fifth Amendment waives default on net leverage ratio covenant as of Dec 31, 2024; covenant testing suspended through March 31, 2025 if milestones met.","Revolving credit commitment capped at outstanding amount; interest rate increased to SOFR + 400 bps; monthly amortization payments required.","Company must achieve refinancing milestones (e.g., term sheet by May 23, 2025) and close refinancing by June 30, 2025.","Unless refinanced by June 30, 2025, Company states it will be unable to pay debt and fund operations; substantial doubt about going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187016,"accession_number":"0001171843-24-006086","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q3 revenue falls 13% to $22M; net loss widens to $4.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $22.0M, down 13.4% YoY from $25.4M; gross margin stable at 58.1%.","GAAP net loss $4.8M (($0.11)/diluted share) vs $1.2M loss a year ago; included $1.2M non-cash pension settlement charge.","Adjusted EBITDA $1.3M (6.0% margin) vs $2.2M (8.9%) prior year; nine-month adjusted EBITDA $4.2M vs $10.9M.","Operations used $0.8M cash in Q3 vs $4.4M generated last year; revolving credit facility constrained by net leverage ratio.","CEO cites challenging market; expects $1M quarterly cost savings from additional actions starting Q4; new products gaining adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":69579000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203551,"accession_number":"0001171843-24-004562","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q2 revenue $23.1M (-20% YoY); GAAP net loss $2.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $23.1M, down 20% from $28.8M; gross margin 57.2% vs 58.0%.","GAAP operating loss $2.1M vs income $0.8M; diluted GAAP EPS -$0.07 vs -$0.02.","Adjusted EBITDA $1.3M (5.5% margin) vs $3.9M (13.6%); adjusted EPS $0.00.","Q2 cash from operations $0.6M vs $5.4M; cost actions expected to save $4M annually.","CEO cites challenging market with recovery delayed to later in second half."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":47609000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220013,"accession_number":"0001171843-24-002878","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harvard Bioscience stockholders elect Alan Edrick, ratify auditor, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Alan Edrick elected Class III director with 19,722,574 votes for, 10,861,497 withheld, 4,292,458 broker non-votes.","Ratification of Grant Thornton LLP as independent auditor for FY2024: 34,794,995 for, 73,003 against, 8,531 abstain.","Non-binding advisory vote on named executive officer compensation approved: 27,472,149 for, 903,608 against, 2,208,314 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220012,"accession_number":"0001171843-24-002591","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q1 revenue falls 18% to $24.5M; posts GAAP net loss of $4.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $24.5M, down 18% YoY from $30.0M; gross margin 60.3% vs 61.2%.","GAAP net loss $4.7M ($0.11 loss per share) vs net income $0.6M ($0.01 EPS) a year ago.","Adjusted operating income $1.2M, down from $4.4M; adjusted EBITDA $1.6M, down from $4.8M.","CEO cites APAC market headwinds and strong prior-year comp; cost reduction initiative announced post-quarter.","Expects solid growth in second half aided by new product launches and Chinese stimulus."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":24512000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220011,"accession_number":"0001171843-24-001791","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience receives $3.1M ERC cash in Q1, expects another $3.1M; amends credit EBITDA addbacks","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $3.1M cash in Q1 2024 from employee retention credits (ERC); expects additional $3.1M in FY2024.","Will incur ~$1M commission fee on ERC; credit agreement amended to exclude fee and $600K escheatment reserves from EBITDA cap.","Third amendment to credit agreement allows add-backs beyond 10% EBITDA cap for those specific items, easing covenant compliance.","No fees payable for amendment except reimbursable attorney costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239750,"accession_number":"0001171843-24-001609","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Harvard Bioscience approves 2024 cash incentive plan for CEO and CFO","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Compensation Committee approved 2024 annual cash incentive plan on March 21, 2024.","CEO and CFO each assigned a target award as a percentage of 2024 base salary.","Payout ranges from 0% to 150% of target based on corporate financial objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239749,"accession_number":"0001171843-24-001222","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q4 2023 revenue $28.2M, guides 2024 flat-to-modest growth, margin improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $28.2M, down 1% YoY; gross margin 58.0%, up 230 bps YoY.","Q4 net loss $1.8M, adj. EPS $0.04; adj. EBITDA $3.6M (13% margin).","FY2023 revenue $112.3M, down 1% YoY; adj. EBITDA $14.6M (13% vs 9.6% prior year).","Debt reduced by $10.5M in 2023; net leverage improved from 4.0x to 2.3x.","2024 guidance: flat to modest revenue growth; gross margin ~60%; adj. EBITDA margin mid-teens."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239748,"accession_number":"0001171843-24-000099","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Harvard Bioscience prelim FY2023 revenue ~$112.3M; includes $5.1M discontinued product headwind","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2023 revenue estimate of ~$112.3M, down from $113.3M in FY2022, with $5.1M net headwind from discontinued products.","Adjusted EBITDA for YTD Q3 2023 was $10.9M (13% of revenue), up 53% vs prior year; FY2022 adjusted EBITDA margin was 9.6%.","Company cites Covid portfolio optimization and supply chain challenges as revenue headwinds.","Guidance from Q3 2023 earnings (Nov 7, 2023) was for FY23 revenue down 11-14%; this presentation does not reaffirm guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":112250000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257265,"accession_number":"0001171843-23-006794","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q3 revenue $25.4M (-6% YoY); adjusted EBITDA margin 8.9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 revenues $25.4M vs $26.9M prior year; gross margin improved to 58.1% from 45.2%.","GAAP net loss $1.2M ($0.03/share); adjusted EPS $0.01; adjusted EBITDA $2.2M (8.9% margin).","Operating cash flow $4.4M; debt reduced $2.8M in Q3, total debt $38.7M.","Updated FY2023 guidance: revenue approx flat YoY, gross margin ~60%, adjusted EBITDA margin 13%-14%.","Asia headwinds and $1.3M revenue impact from discontinued products; North America revenue grew."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":84097000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274596,"accession_number":"0001171843-23-005063","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q2 revenue $28.8M; adj. op. income up to $3.6M; guides FY23 $116-120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $28.8M (-1% YoY) as discontinued product headwinds ($1.6M) offset new product growth.","GAAP op. income $0.8M (prior year included $4.9M litigation reversal); adj. op. income rose to $3.6M from $3.1M.","Net loss $1.0M ($0.02 loss/share) vs. net income $2.4M; adjusted EPS $0.04 vs. $0.05.","H1 cash from ops $5.4M; net debt reduced $5.4M YTD to $37.8M.","FY2023 guidance: revenue $116-120M, gross margin ~60%, adj. EBITDA margin 15-17%, net leverage ~2x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":58734000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291900,"accession_number":"0001171843-23-003988","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience appoints Jennifer Cote as permanent CFO; $300k base salary, 50% bonus target","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Cote, previously interim CFO since January 2023, appointed permanently as CFO and Treasurer effective June 19, 2023.","Employment agreement includes base salary of $300,000 and annual bonus target of 50% of base salary.","Prior to HBIO, Cote held finance leadership roles at Bose Corporation and was an Audit Manager at Arthur Andersen.","Cote is a CPA and CGMA; she joined the company as VP of Global Finance in May 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291899,"accession_number":"0001171843-23-003310","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harvard Bioscience shareholders re-elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Katherine A. Eade and Thomas W. Loewald re-elected as Class II directors with over 24.5M and 25.5M votes for, respectively.","Grant Thornton LLP ratified as independent auditor for FY2023 with 33.3M votes for, only 9,580 against.","Non-binding advisory vote on executive compensation approved (26.6M for vs 531,708 against).","Shareholders recommended a 1-year frequency for future say-on-pay votes (25.4M for 1 year); board adopted annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291898,"accession_number":"0001171843-23-002499","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q1 revenue $30M (+4% YoY); net income $0.6M vs $6.9M loss; adj EBITDA margin 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $30.0M, up 4% from $28.8M in Q1'22; gross margin improved to 61% from 56%.","GAAP net income $0.6M ($0.01 diluted EPS) vs net loss of $6.9M ($0.17 loss) in Q1'22.","Adjusted EBITDA $4.8M (16% margin) vs $2.7M (9% margin) in prior year.","Paid down debt by $2.8M; net debt $41.0M; targeting net leverage ~2x by year-end.","Full-year 2023 guidance: mid-single digit revenue growth, gross margins ~60%, adjusted EBITDA margins 16-17%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":29975000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312652,"accession_number":"0001171843-23-001638","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Harvard Bioscience reports de minimis SVB exposure, no material impact expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash held in Silicon Valley Bank accounts is de minimis; expects full access and no material impact on financial condition or operations.","Credit agreement with Citizens Bank, Wells Fargo, and SVB provides $40M term loan and $25M senior revolving credit facility.","Expects sufficient liquidity from cash, operations, and non-SVB lenders even if SVB cannot fund its portion of the credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312651,"accession_number":"0001171843-23-001577","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harvard Bioscience approves 2023 cash incentive plan for CEO and Interim CFO","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Compensation Committee approved 2023 annual cash incentive plan on March 6, 2023.","CEO and Interim CFO receive target award as a percentage of 2023 base salary.","Payout can range from 0% to 150% of target based on corporate financial objectives.","No specific targets, dollar amounts, or performance thresholds disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312650,"accession_number":"0001171843-23-001518","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"HBIO Q4 revenue $28.4M (-14% YoY), GAAP net loss $1.7M; guides low-single-digit growth in FY23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $28.4M, down 14% YoY; negative currency impact of $1.0M.","GAAP operating loss $0.5M vs income $1.7M; GAAP diluted EPS -$0.04 vs $0.02.","Adjusted EPS $0.04 vs $0.08; adjusted EBITDA $3.7M vs $5.7M.","FY23 guidance: low-to-mid single-digit revenue growth, improving gross margin, adjusted EBITDA expansion.","Plans to reduce leverage ratio to ~2x by year end with improved margins and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312649,"accession_number":"0001171843-23-000339","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Michael Rossi resigns from Harvard Bioscience; separation agreement signed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rossi resigned as CFO and Treasurer effective Dec 31, 2022; remains employee through May 10, 2023 for transition.","Will receive base salary during transition period; no 2022 bonus or equity vesting after separation.","Separation Agreement dated Jan 18, 2023 includes release of claims and non-disparagement clauses.","Company to provide only dates of employment for reference inquiries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312648,"accession_number":"0001171843-23-000010","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K/A","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harvard Bioscience sets compensation for Interim CFO Cote: $270K salary, bonus, $75K RSU","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $270,000 as Interim CFO and Treasurer, effective January 1, 2023.","Eligible for cash bonus of 25% of 2023 base salary, paid in quarterly installments.","One-time equity award of RSUs with $75,000 grant date value, vesting December 29, 2023.","Compensation package is in addition to prior VP Finance terms from April 2022 offer letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331165,"accession_number":"0001171843-22-007975","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Harvard Bioscience CFO Michael Rossi resigns; Jennifer Cote named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Rossi resigns as CFO and Treasurer effective Dec 31, 2022; will provide transition assistance through May 10, 2023.","Jennifer Cote, VP of Global Finance since May 2022, appointed Interim CFO and Treasurer effective upon Rossi's departure.","Cote previously held finance leadership roles at Bose Corporation and Arthur Andersen; is a CPA and CGMA.","Company has initiated a search for a permanent CFO to succeed Rossi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331164,"accession_number":"0001171843-22-007231","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q3 revenue down 9% to $26.9M; GAAP operating loss $3.8M vs income $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS ($0.08) vs ($0.00); adjusted diluted EPS ($0.01) vs $0.06.","Pre-clinical product sales fell 17% YoY; cellular/molecular grew 6%; currency headwind ~$1.0M.","Q4 revenue guided to ~$30M with adjusted operating margin 14-15% (Q3 margin 2.6%).","Portfolio optimization to yield ~$4.0M annual gross margin improvement and ~$1.5M opex reduction entering 2023.","Net debt increased to $45.0M from $40.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":84908000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348732,"accession_number":"0001171843-22-005340","cik":1123494,"company_name":"HARVARD BIOSCIENCE INC","ticker":"HBIO","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Harvard Bioscience Q2 revenue flat, cuts workforce; guides to 1-5% growth and 13-14% op margin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue flat at $29.2M; GAAP operating income $4.0M includes $4.9M litigation benefit.","Adjusted operating income $3.1M vs $4.3M YoY; adjusted EPS $0.05 vs $0.06.","Gross margin improved to 58% from 57%.","Company discontinuing non-strategic products and cutting ~5% of global workforce.","FY2022 guidance: 1-5% reported revenue growth; adjusted operating margin 13-14%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":57986000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25933546.539792385,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-04T23:59:59+00:00|348732"}